Clinical Trials Logo

Mononegavirales Infections clinical trials

View clinical trials related to Mononegavirales Infections.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04644484 Completed - Virus Diseases Clinical Trials

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

Start date: September 23, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3, blinded, randomized study of SYN023 compared to a China licensed Human Rabies Immunoglobulin (a Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP). The trial will enroll the World Health Organization (WHO) Category III rabies exposure subjects. The subject's death and rabies data will be reviewed by Data and safety monitoring board (DSMB) to confirm the safety. Besides, rabies vaccine would be administered after Study Drug in each group. This trial is proposed to further the licensure of SYN023 to provide an effective PEP alternative available to those exposed persons who need such a product. A placebo-controlled rabies trial is unethical thus HRIG is selected as the control group. Rabies immune globulin from equine and human sources (HRIG) have been evaluated in many trials and HRIG is the standard of care in China.